U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H15NO.ClH
Molecular Weight 201.693
Optical Activity ( + )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Pseudoephedrine hydrochloride

SMILES

Cl.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1

InChI

InChIKey=BALXUFOVQVENIU-KXNXZCPBSA-N
InChI=1S/C10H15NO.ClH/c1-8(11-2)10(12)9-6-4-3-5-7-9;/h3-8,10-12H,1-2H3;1H/t8-,10+;/m0./s1

HIDE SMILES / InChI
Molecular Formula C10H15NO
Molecular Weight 165.2322
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12373557 | http://www.mayoclinic.org/drugs-supplements/ephedra--ma-huang/background/hrb-20059270 | https://www.sudafed.com/adult-products/congestion/sudafed-24-hour#uses-and-directions | https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0011888 | https://www.ncbi.nlm.nih.gov/pubmed/11772135 | https://www.ncbi.nlm.nih.gov/pubmed/10449190 | https://www.ncbi.nlm.nih.gov/pubmed/12954796

Pseudoephedrine is a sympathomimetic drug. Pseudoephedrine acts as an adrenomimetic and inhibitor of monoamine transporters. Ephedra sinica, a species of ephedra (ma huang), contains ephedrine and pseudoephedrine. Ephedra has been found to stimulate the nervous system, increase airflow into the lungs and constrict blood vessels. In combination with caffeine, ephedra appears to cause weight loss. Pseudoephedrine is a decongestant that shrinks blood vessels in the nasal passages. Pseudoephedrine is used to relieve nasal or sinus congestion caused by the common cold, sinusitis, and hay fever and other respiratory allergies.

CNS Activity

Originator

Ladenburg, A.
4
Sources: A. Ladenburg, C. Oelschlägel, Ber. 22, 1823 (1889).
Curator's Comment: (+)-threo-isomer of ephedrine, q.v. Isoln from E. vulgaris: A. Ladenburg, C. Oelschlägel, Ber. 22, 1823 (1889). Synthesis: E. Späth, R. Göhring, Monatsh. Chem. 41, 319 (1920). reference retrieved from http://www.drugfuture.com/chemdata/pseudoephedrine.html

Approval Year

1961
146
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 5.6 µM [IC50]
Inhibitor
8504
 1.18 µM [IC50]
Agonist
2752
Agonist
2752
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
SUDAFED 24 HOUR

Approved Use

temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies; reduces swelling of nasal passages; relieves sinus pressure

Launch Date

1992
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
292 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/073585Orig1s000.pdf
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4346 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/073585Orig1s000.pdf
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.3 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/073585Orig1s000.pdf
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
unknown, 16 years
Health Status: unknown
Age Group: 16 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
Other AEs: Rhabdomyolysis, Creatine kinase increased...
Other AEs:
Rhabdomyolysis (1 patient)
Creatine kinase increased (1 patient)
Blood myoglobin increased (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Other AEs: Tension, Dry mouth...
Other AEs:
Tension (10 patients)
Dry mouth (6 patients)
Tachycardia (9 patients)
Palpitations (10 patients)
Anxiety (13 patients)
Insomnia (12 patients)
Anorexia (7 patients)
Restlessness (10 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
90 mg 1 times / day multiple, oral
Overdose
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
unhealthy, 3 years
Health Status: unhealthy
Age Group: 3 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
Disc. AE: Urinary retention...
AEs leading to
discontinuation/dose reduction:
Urinary retention (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 37 years
Health Status: unhealthy
Age Group: 37 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
720 mg 1 times / day multiple, oral
Highest studied dose
Dose: 720 mg, 1 times / day
Route: oral
Route: multiple
Dose: 720 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23918202
unhealthy, 38.8 years
Health Status: unhealthy
Age Group: 38.8 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23918202
Sources:
https://pubmed.ncbi.nlm.nih.gov/23918202
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 44 years
Health Status: unhealthy
Age Group: 44 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 46 years
Health Status: unhealthy
Age Group: 46 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 50 years
Health Status: unhealthy
Age Group: 50 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
720 mg single, oral
Overdose
Dose: 720 mg
Route: oral
Route: single
Dose: 720 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
unhealthy, 87 years
Health Status: unhealthy
Age Group: 87 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
Other AEs: Hypertension...
Other AEs:
Hypertension (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
AEs

AEs

AESignificanceDosePopulation
Blood myoglobin increased 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
unknown, 16 years
Health Status: unknown
Age Group: 16 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
Creatine kinase increased 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
unknown, 16 years
Health Status: unknown
Age Group: 16 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
Rhabdomyolysis 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
unknown, 16 years
Health Status: unknown
Age Group: 16 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
Palpitations 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Restlessness 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Tension 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Insomnia 12 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Anxiety 13 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Dry mouth 6 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Anorexia 7 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Tachycardia 9 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Urinary retention acute, 1 patient
Disc. AE
90 mg 1 times / day multiple, oral
Overdose
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
unhealthy, 3 years
Health Status: unhealthy
Age Group: 3 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
Ischemic colitis 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 37 years
Health Status: unhealthy
Age Group: 37 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Abdominal pain acute, 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 37 years
Health Status: unhealthy
Age Group: 37 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Ischemic colitis 1 patient
Disc. AE
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 44 years
Health Status: unhealthy
Age Group: 44 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Abdominal pain acute, 1 patient
Disc. AE
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 44 years
Health Status: unhealthy
Age Group: 44 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Ischemic colitis 1 patient
Disc. AE
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 46 years
Health Status: unhealthy
Age Group: 46 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Abdominal pain acute, 1 patient
Disc. AE
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 46 years
Health Status: unhealthy
Age Group: 46 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Ischemic colitis 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 50 years
Health Status: unhealthy
Age Group: 50 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Abdominal pain acute, 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 50 years
Health Status: unhealthy
Age Group: 50 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Hypertension 1 patient
720 mg single, oral
Overdose
Dose: 720 mg
Route: oral
Route: single
Dose: 720 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
unhealthy, 87 years
Health Status: unhealthy
Age Group: 87 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:51209
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:51209
eMolecules
494893
https://www.emolecules.com/cgi-bin/more?vid=494893
ZINC
ZINC000000020259
http://zinc15.docking.org/substances/ZINC000000020259
PubMed

PubMed

TitleDatePubMed
Development and validation of a capillary zone electrophoresis method for the determination of ephedrine and related compounds in urine without extraction.
2003-07-05
Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs.
2003-07
Chiral analysis of amphetamine-type stimulants using reversed-polarity capillary electrophoresis/positive ion electrospray ionization tandem mass spectrometry.
2003-06
Press-coating of immediate release powders onto coated controlled release tablets with adhesives.
2003-05-20
Exemption of chemical mixtures containing the List I chemicals ephedrine, N-methylephedrine, N-methylpseudoephedrine, norpseudoephedrine, phenylpropanolamine, and pseudoephedrine. Final rule.
2003-05-01
In vitro evaluation of apical microleakage following canal filling with a coated carrier system compared with lateral and thermomechanical Gutta-Percha condensation techniques.
2003-05
A comparative study of root canal preparation using FlexMaster and HERO 642 rotary Ni-Ti instruments.
2003-05
Canine model of nasal congestion and allergic rhinitis.
2003-05
Controlled porosity osmotic pump-based controlled release systems of pseudoephedrine. I. Cellulose acetate as a semipermeable membrane.
2003-04-14
Baboon syndrome due to pseudoephedrine.
2003-04
[Improving the medical treatment of minors who are victims of sexual assault or physical abuse: a receiving center and partnership between a psychiatric hospital and university hospital].
2003-04
Sensitive determination of ephedrine and pseudoephedrine by capillary electrophoresis with laser-induced fluorescence detection.
2003-04
Surfing, self-medicating and safety: buying non-prescription and complementary medicines via the internet.
2003-04
Nonpigmenting solitary fixed drug eruption caused by a Chinese traditional herbal medicine, ma huang (Ephedra Hebra), mainly containing pseudoephedrine and ephedrine.
2003-04
Spectrophotometric determination of binary mixtures of pseudoephedrine with some histamine H1-receptor antagonists using derivative ratio spectrum method.
2003-03-26
Adrenaline given outside the context of life threatening allergic reactions.
2003-03-15
[Tobacco: knowledge, reasoning and opinion of high school students in Doubs. Reflections on prevention].
2003-03
Safety of selegiline with cold medications.
2003-03
Separation and determination of ephedrine and pseudoephedrine by combination of flow injection with capillary electrophoresis.
2003-01
Physiological, subjective and performance effects of pseudoephedrine and phenylpropanolamine during endurance running exercise.
2003-01
Efficacy and safety of clemastine-pseudoephedrine-acetaminophen versus pseudoephedrine-acetaminophen in the treatment of seasonal allergic rhinitis in a 1-day, placebo-controlled park study.
2003-01
Pharmacokinetic interaction study of a fixed combination of 500 mg acetylsalicylic acid/30 mg pseudoephedrine versus each of the single active ingredients in healthy male volunteers.
2003
Evaluation of a pseudoephedrine linker for asymmetric alkylations on solid phase.
2002-12-26
Efficacy of once-daily desloratadine/pseudoephedrine for relief of nasal congestion.
2002-12-13
Enhanced enantio- and diastereoselectivity via confinement and cation binding: yang photocyclization of 2-benzoyladamantane derivatives within zeolites.
2002-11-29
Quantitative and structural determination of pseudoephedrine sulfate and its related compounds in pharmaceutical preparations using high-performance liquid chromatography.
2002-11-07
[Bacteremia caused by coagulase-negative staphylococci: incidence, frequency of teicoplanin resistance and molecular epidemiology].
2002-11
A moderate dose of pseudoephedrine does not alter muscle contraction strength or anaerobic power.
2002-11
Enantiomeric separation of methamphetamine and related analogs by capillary zone electrophoresis: intelligence study in routine methamphetamine seizures.
2002-11
Pharmacological characterization of a noninvasive, chronic, experimental dog model of nasal congestion.
2002-10-22
[Blood supply of the lips].
2002-10
[Cutaneous complications following liver transplantation: epidemiologic and clinical study in 86 patients].
2002-10
Enzymatic (R)-phenylacetylcarbinol production in benzaldehyde emulsions.
2002-10
Stereospecific inhibition of monoamine uptake transporters by meta-hydroxyephedrine isomers.
2002-10
Severe adverse drug reactions due to pseudoephedrine from over-the-counter medications.
2002-09
[Toxic dermatitis caused by pseudoephedrine: apropos of a case].
2002-09
Erythrodermia to pseudoephedrine in a patient with contact allergy to phenylephrine.
2002-08-30
Rapid simultaneous determination of amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine, 3,4-methylenedioxymethamphetamine, and 3,4-methylenedioxyethylamphetamine in urine by solid-phase extraction and GC-MS: a method optimized for high-volume laboratories.
2002-08-09
[An open label multi-center clinical trial to evaluate the efficacy of compound pseudoephedrine [corrected] hydrochloride sustained release capsules in patients with nasal symptoms associated with common cold].
2002-08
Generalized dermatitis due to pseudoephedrine.
2002-08
Modifying the bitterness of selected oral pharmaceuticals with cation and anion series of salts.
2002-07
Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit.
2002-07
A comparative study of the side effects between pseudoephedrine in Loratadine plus Pseudoephedrine Sulfate Repetabs Tables and loratadine + pseudoephedrine tablet in treatment of allergic rhinitis in Thai patients.
2002-06
Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use.
2002-06
Pseudoephedrine as a chiral auxiliary for asymmetric Michael reactions: synthesis of 3-aryl-delta-lactones.
2002-05-30
Pigmented purpuric dermatosis due to pseudoephedrine.
2002-05
Myocardial infarction temporally related to ephedra--a possible role for the coronary microcirculation.
2002
Liquid chromatography/tandem mass spectrometric bioanalysis using normal-phase columns with aqueous/organic mobile phases - a novel approach of eliminating evaporation and reconstitution steps in 96-well SPE.
2002
Epinephrine analogues.
2001-11
[Separation and determination of pseudoephedrine in bufferin cold tablet by capillary electrophoresis with hydropropyl-beta-cyclodextrin as chiral selective reagent].
2001-11
Patents

Patents

05560921
4
06835559
6
07888040
4
JP2002316927A
5
JP2002332229A
4
JP2003089638A
4
JP2007176958A
4
JP2007525670A
150
JP2008081510A
4
JP2008510795A
76
JP2010241834A
10
JP2010270109A
4
JP3553083B2
51
JPH02134A
4
JPS62221625A
4

Sample Use Guides

In Vivo Use Guide
SUDAFED® 24 HOUR TABLET, EXTENDED RELEASE; ORAL (PSEUDOEPHEDRINE HYDROCHLORIDE) 240MG adults and children 12 years and older: a tablet with water every 24 hours children under 12 years: do not use this product in children under 12 years of age
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Pseudoephedrine inhibits interleukin-2 (IL-2) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.
Unknown
Substance Class Chemical
Created
by admin
on Wed Apr 02 13:38:33 GMT 2025
Edited
by admin
on Wed Apr 02 13:38:33 GMT 2025
Record UNII
6V9V2RYJ8N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACTAHIST COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Preferred Name English
Pseudoephedrine hydrochloride
EP   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
CODIMAL-L.A. 12 COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
BROMANATE DM COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
ALLERFED COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
RHINALAIR
Brand Name English
SINE-AID IB COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
TRIACIN-C COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
TRIPHED COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
MYFED COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
HISTAFED COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
ALLEGRA-D COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
TRILITRON COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE [MART.]
Common Name English
CORPHED COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
GALSUD
Brand Name English
DIMETANE-DX COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
SEMPREX-D COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
CHILDREN'S ADVIL COLD COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
SUDAFED
Brand Name English
PSEUDOEPHEDRINE HYDROCHLORIDE [USP-RS]
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE [MI]
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE [USAN]
Common Name English
OTRINOL
Brand Name English
ZYRTEC-D COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
NSC-33634
Code English
BROMFED-DM COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
Pseudoephedrine hydrochloride [WHO-DD]
Common Name English
CHILDREN'S MOTRIN COLD COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE [VANDF]
Common Name English
EFIDAC 24
Brand Name English
PSEUDOEPHEDRINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
PSEUDOEPHEDRINE HCL
Common Name English
MUCINEX D COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
ADVIL ALLERGY SINUS COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
ALEVE-D COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
ACTIFED COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
GALPSEUD
Brand Name English
ISOCLOR COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
NSC-106567
Code English
Classification Tree Code System Code
NCI_THESAURUS C29709
Created by admin on Wed Apr 02 13:38:33 GMT 2025 , Edited by admin on Wed Apr 02 13:38:33 GMT 2025
CFR 21 CFR 341.20
Created by admin on Wed Apr 02 13:38:33 GMT 2025 , Edited by admin on Wed Apr 02 13:38:33 GMT 2025
DEA NO. 8112
Created by admin on Wed Apr 02 13:38:33 GMT 2025 , Edited by admin on Wed Apr 02 13:38:33 GMT 2025
Code System Code Type Description
NSC
106567
Created by admin on Wed Apr 02 13:38:33 GMT 2025 , Edited by admin on Wed Apr 02 13:38:33 GMT 2025
PRIMARY
DAILYMED
6V9V2RYJ8N
Created by admin on Wed Apr 02 13:38:33 GMT 2025 , Edited by admin on Wed Apr 02 13:38:33 GMT 2025
PRIMARY
SMS_ID
100000092030
Created by admin on Wed Apr 02 13:38:33 GMT 2025 , Edited by admin on Wed Apr 02 13:38:33 GMT 2025
PRIMARY
EVMPD
SUB04119MIG
Created by admin on Wed Apr 02 13:38:33 GMT 2025 , Edited by admin on Wed Apr 02 13:38:33 GMT 2025
PRIMARY
RS_ITEM_NUM
1581005
Created by admin on Wed Apr 02 13:38:33 GMT 2025 , Edited by admin on Wed Apr 02 13:38:33 GMT 2025
PRIMARY
NCI_THESAURUS
C29390
Created by admin on Wed Apr 02 13:38:33 GMT 2025 , Edited by admin on Wed Apr 02 13:38:33 GMT 2025
PRIMARY
ChEMBL
CHEMBL1590
Created by admin on Wed Apr 02 13:38:33 GMT 2025 , Edited by admin on Wed Apr 02 13:38:33 GMT 2025
PRIMARY
EPA CompTox
DTXSID10889343
Created by admin on Wed Apr 02 13:38:33 GMT 2025 , Edited by admin on Wed Apr 02 13:38:33 GMT 2025
PRIMARY
CAS
345-78-8
Created by admin on Wed Apr 02 13:38:33 GMT 2025 , Edited by admin on Wed Apr 02 13:38:33 GMT 2025
PRIMARY
RXCUI
91168
Created by admin on Wed Apr 02 13:38:33 GMT 2025 , Edited by admin on Wed Apr 02 13:38:33 GMT 2025
PRIMARY RxNorm
NSC
33634
Created by admin on Wed Apr 02 13:38:33 GMT 2025 , Edited by admin on Wed Apr 02 13:38:33 GMT 2025
PRIMARY
ECHA (EC/EINECS)
206-462-1
Created by admin on Wed Apr 02 13:38:33 GMT 2025 , Edited by admin on Wed Apr 02 13:38:33 GMT 2025
PRIMARY
DRUG BANK
DBSALT000149
Created by admin on Wed Apr 02 13:38:33 GMT 2025 , Edited by admin on Wed Apr 02 13:38:33 GMT 2025
PRIMARY
PUBCHEM
9581
Created by admin on Wed Apr 02 13:38:33 GMT 2025 , Edited by admin on Wed Apr 02 13:38:33 GMT 2025
PRIMARY
FDA UNII
6V9V2RYJ8N
Created by admin on Wed Apr 02 13:38:33 GMT 2025 , Edited by admin on Wed Apr 02 13:38:33 GMT 2025
PRIMARY
MERCK INDEX
m9294
Created by admin on Wed Apr 02 13:38:33 GMT 2025 , Edited by admin on Wed Apr 02 13:38:33 GMT 2025
PRIMARY Merck Index
Related Record Type Details
Structure of Pseudoephedrine hydrochloride
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
Term
Structure of PSEUDOEPHEDRINE
PARENT -> SALT/SOLVATE
Structure of Pseudoephedrine hydrochloride
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Structure of PSEUDOEPHEDRINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of Pseudoephedrine hydrochloride
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N-nitroso-pseudoephedrine
IMPURITY -> PARENT
Related Record Type Details
Structure of PSEUDOEPHEDRINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966